Prima BioMed gets approval for IMP321 Phase I trial to treat solid tumours

Australian biotechnology firm Prima BioMed ’s German collaboration partner the Institute of Clinical Cancer Research has secured regulatory and ethical approvals for the initiation of a Phase I clinical trial (INSIGHT) of IMP321 to treat solid tumours…
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news